Given our observation that RAC1-amplified HNSCC were pharmacologically vulnerable to EHop-016, we tested the hypothesis that RAC1-amp status in other cancer, such as melanoma, might also confer sensitivity to Rac1 targeting using EHop-016. The gene discussed is RAC1; the disease is melanoma.